Ofatumumab-mediated CD20+ B-cell depletion promotes neuromuscular junction functional recovery and sustains long-term efficacy in refractory generalized myasthenia gravis
Ofatumumab provides durable clinical benefit and steroid-sparing effects, and its sustained depletion of CD20-positive B cells may facilitate recovery of neuromuscular junction transmission. These findings support its potential application within the field of regenerative pharmacology.
Authors
- Yudan Liu (ORCID: https://orcid.org/0000-0002-7496-7033)
- Zhuangzhuang Ren
- Yanhua Yang (ORCID: https://orcid.org/0000-0002-7916-3683)
- Yan Wang (ORCID: https://orcid.org/0000-0002-6108-2025)
- Yuping Chen (ORCID: https://orcid.org/0000-0001-8477-6321)
- Feng Qiu (ORCID: https://orcid.org/0000-0003-3795-7976)
- Shengjie Xu (ORCID: https://orcid.org/0000-0003-2716-6230)
Institutions
- Chinese PLA General Hospital (CN)
- PLA 306 Hospital (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-11-27
- DOI
- https://doi.org/10.3389/fphar.2025.1728721
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 0.00